Recombinant humanized antivascular endothelial growth factor (rhuMAbVEGF) is a monoclonal IgG, antibody that is being developed as an antiangiogenic agent for use in treating a variety of solid tumors. Preclinical safety studies included an immunohistochemical tissue cross-reactivity study, in vitro hemolytic potential and blood compatibility studies, and multiple dose toxicity studies. Toxicity studies were conducted in cynomolgus monkey because rhuMAbVEGF is pharmacologically active in this species and does not bind rat or mouse vascular endothelial growth factor (VEGF). Following twice weekly administration of rhuMAbVEGF for 4 or 13 wk, young adult cynomolgus monkeys exhibited physeal dysplasia characterized by a dose-related increase in hypertrophied chondrocytes, subchondral bony plate formation, and inhibition of vascular invasion of the growth plate. In addition, decreased ovarian and uterine weights and an absence of corpora lutea were observed in females receiving 10 and 50 mg/kg/dose in the 13-wk study. Both the physeal and ovarian changes were reversible with cessation of treatment. No other treatment-related effects were observed following rhuMAbVEGF administration at doses up to 50 mg/kg. These findings indicate that VEGF is required for longitudinal bone growth and corpora lutea formation and that rhuMAbVEGF can reversibly inhibit physiologic neovascularization at these sites.
Adamis AP, Shima DT, Tolentino M., Gragoudas E., Ferrara N., Folkman J., D'Amore PA, and Miller JW (1996). Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch. Ophthalmol.114: 66-71.
2.
Aiello LP, Avery R., Arrigg R., Keyt B., Jampel H., Shah S., Pasquale L., Thieme H., Iwamoto M., Park JE, Nguyen H., Aiello LM, Ferrara N., and King GL (1994). Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N. Eng. J. Med.331: 1480-1487.
3.
Alini M., Marriott A., Chen T., Abe S., and Poole AR (1996). A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation. Dev. Biol.176: 124-132.
4.
Baird A. and Bohlen P. (1990). Fibroblast growth factors. In: Handbook of Experimental Pharmacology, MB Sporn and AB Roberts, (eds). Springer, Berlin, pp. 369-418.
5.
Bassett Del (1943). The changes in the vascular pattern of the ovary of the albino rat during the estrus cycle. Am. J. Anat.73: 251-278.
6.
Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A., Clark WC, Robertson JT, Ali IU, and Oldenfield EH (1993). Expression of the vascular permeability/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest.91: 153-159.
7.
Berse B., Brown LF, Van de Water L., Dvorak HF, and Senger DR (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol. Biol. Cell3: 211-218.
8.
Borgström P. , Hillan KJ, Sriramarao P., and Ferrara N. (1996). Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibodies. Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res.56: 4032-4039.
9.
Brown LF, Berse B., Jackman RW, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, and Schnitt SJ (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol.26: 86-91.
10.
Brown LF, Berse B., Jackman RW, Tognazzi K., Manseau EJ, Dvorak HF, and Senger DR (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol.143: 1255-1262.
11.
Brown LF, Berse B., Jackman RW, Tognazzi K., Manseau EJ, Senger DR, and Dvorak HF (1993). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res.53: 4727-4735.
12.
Brown LF, Berse B., Tognazzi K., Manseau EJ, Van de Water L., and Senger DR (1992). Vascular cell permeability factor mRNA and protein expression in the human kidney. Kidney Int.42: 1457-1461.
13.
Carmeliet P. , Ferreria V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., and Nagy A. (1996). Abnormal blood vessels development and lethality in embryos lacking a single VEGF allele. Nature (Lond.) 380: 435-439.
14.
Carter P., Presta L., Gorman CM, Ridgway Jbb, Henner D., Wong Wlt, Rowland AM, Knotts C., Carver ME, and Shepard HM (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA89: 4285-4289.
15.
Center for Biologics Evaluation and Research, Food and Drug Administration (1997). Points to consider in the manufacture and testing of monoclonal antibody products for human use. CBER, Food and Drug Administration, Washington, D.C.
16.
de Vries C. , Escobedo JA, Ueno H., Houck K., Ferrara N., and Williams LT (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor . Science255: 989-991.
17.
Detmar M., Brown LF, Claffey KP, Yeo KT, Kocher O., Jackman RW, Berse B., and Dvorak HF (1994). Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med.180: 1141-1146.
18.
Dvorak HF, Brown LF, Detmar M., and Dvorak AM (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis. Am. J. Pathol.146: 1029-1039.
19.
Eigenbrot C. , Gonzales T., Mayeda J., Carter P., Werther W., Hotaling T., Fox JA, and Kessler J. (1994). X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD-18 antibody: Structural indications of the key role of VH residues 59-65. Proteins18: 49-62.
20.
Eigenbrot C. , Randal M., Presta L., and Kossiakoff AA (1993). X-ray structure of the antigen-binding domain from 3 variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J. Mol. Biol.229: 969-995.
21.
Fava RA, Olsen NJ, Spencer-Green G., Yeo T-K., Yeo K-T., Berse B., Jackman RW, Senger DR, Dvorak HF, and Brown LF (1994). Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid arthritis. J. Exp. Med.180: 340-346.
22.
Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea KS, Powell-Braxton L., Hillan KJ, and Moore MW (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (Lond) 380: 439-442.
23.
Ferrara N., Chen H., Davis-Smyth T., Gerber HP, Nguyen T-N., Peers D., Chisholm V., Hillan KJ, and Schwall RH (1998). Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med.4: 336-340.
24.
Ferrara N. and Davis-Smyth T. (1997). The biology of vascular endothelial growth factor . Endocr. Rev.18: 425.
25.
Ferrara N. and Henzel WJ (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun.161: 851-858.
26.
Ferrara N., Leung DW, and Phillips HS (1991). Molecular characterization and distribution of vascular endothelial growth factor. In: Neuroendocrine Perspectives , RB McClead and EE Muller, (eds). Springer/Verlag , New York, pp. 127-150.
27.
Ferrara N., Winer J., and Burton T. (1991). Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors5: 141-148.
28.
Folkman J. and Shing Y. (1992). Angiogenesis. J. Biol. Chem.267: 10931-10934.
29.
Garner A. (1994). Vascular diseases. In: Pathobiology of Ocular Diseases. A Dynamic Approach, A Garner and GK Klintworth, (eds). Marcel Dekker, New York, pp. 1625-1710.
30.
Hanahan D. (1997). Signaling vascular morphogenesis and maintenance . Science277: 48-50.
31.
Houck KA, Ferrara N., Winer J., Cachianes G., Li B., and Leung DW (1991). The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol.5: 1806-1814.
32.
Houck KA, Leung DW, Rowland AM, Winer J., and Ferrara N. (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem.267: 26031-26037.
33.
Hunziker EB , Schenk RB, and Cruz-Orive L-M. (1987). Quantitation of chondrocyte performance in growth plate cartilage during longitudinal bone growth. J. Bone Joint Surg.69A: 162-173.
34.
Iannotti JP (1990). Growth plate physiology and pathology. In: Pathologic Fractures in Metabolic Bone Disease, The Orthopedic Clinics of North America, Philadelphia, pp. 1-17.
35.
Jakeman LB, Altar CA, Winer J., Bennett G., and Ferrara N. (1992). Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J. Clin. Invest.89: 244-253.
36.
Jakeman LB, Armanini M., Phillips HS, and Ferrara N. (1993). Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology133: 848-859.
37.
Jones PT, Dear PH, Foote J., Neuberger MS, and Winter G. (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (Lond) 321: 522-525.
38.
Kamat BR, Brown LF, Manseau EJ, Senger DR, and Dvorak HF (1995). Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Am. J. Pathol.146: 157-165.
39.
Kaplan SL and Grumbach MM (1990). Pathophysiology and treatment of sexual precocity . J. Clin. Endocrinol. Metab.71: 785-789.
40.
Kim KJ, Li B., Houck K., Winer J., and Ferrara N. (1992). The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors7: 53-64.
41.
Kim KJ, Li B., Winer J., Armanini M., Gillett N., Phillips HS, and Ferrara N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond) 362: 841-844.
42.
Kitamoto Y. , Tokunaga H., and Tomita K. (1997). Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis. J. Clin. Invest.99: 2351-2357.
43.
Klagsbrun M. and D'Amore PA (1991). Regulators of Angiogenesis . Annu. Rev. Physiol.53: 217-239.
44.
Klagsbrun M. and Smith S. (1980). Purification of a cartilage-derived growth factor. J. Biol. Chem.255: 10859-10866.
45.
Koch AE, Harlow L., Haines GK, Amento EP, Unemori EN, Wong W-L., Pope RM, and Ferrara N. (1994). Vascular endothelial growth factor: A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol.152: 4149-4155.
46.
Leung DW, Cachianes G., Kuang W-J., Goeddel DV, and Ferrara N. (1989). Vascular endothelial growth factor, a secreted angiogenic mitogen. Science246: 1306-1309.
47.
Lobb R., Sasse J., Sullivan R., Shing Y., D'Amore P., Jacobs J., and Klagsbrun M. (1986). Purification and characterization of heparin-binding endothelial cell growth factors. J. Biol. Chem.261: 1924-1928.
48.
Lopez PF, Sippy BD, Lambert HM, Thach AB, and Hinton DR (1996). Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes . Invest. Ophthalmol. Vis. Sci.37: 855-868.
49.
Maisonpierre PC. Suri C. Jones PF. Bartunkova S., Weigand SJ, Radziejewski C., Compton D. McClain J., Aldrich TH, Papadopoulos N., Daly TJ, Davis S. Sato TN, and Yancopoulos GD (1997). Angiopoietin-2, a natural antagonist for Tie 2 that disrupts in vivo angiogenesis. Science277: 55-60.
50.
Mattern J., Koomagi R., and Volm M. (1996). Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer.73: 931-934.
51.
McFarland CD , Brown RA, McLaughlin B., Ali SY, and Weiss JB (1990). Production of an endothelial cell stimulating angiogenesis factor (ESAF) by chondrocytes during in vitro cartilage calcification. Bone Miner.11: 319-333.
52.
Melnyk O., Schuman MA, and Kim KJ (1996). Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth . Cancer Res.56: 921-924.
53.
Millauer B. , Wizigmann-Voos S., Schnurch H., Martinez R., Moller Nph, Risau W., and Ullrich A. (1993). High affinity VEGF binding and developmental expression suggest fik-1 as a major regulator of vasculogenesis and angiogenesis. Cell72: 835-846.
54.
Miller RA, Oseroff AR, Stratte PT, and Levy R. (1983). Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood62: 988-995.
55.
Minchenko A. , Bauer T., Salceda S., and Caro J. (1994). Hypoxic stimulation of vascular endothelial growth factor expression in vivo and in vitro. Lab. Invest.71: 374-379.
56.
Monacci WT, Merrill MJ, and Oldfield EH (1993). Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am. J. Physiol.264: 995-1002.
57.
Neuberger MS , Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, and Rabbits TH (1985). A hapten-specific chimeric IgE antibody with human physiological effector function. Nature (Lond) 314: 268-270.
58.
Park JE, Keller GA, and Ferrara N. (1993). The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of ECM-bound VEGEMol. Biol. Cell4: 1317-1326.
59.
Plate KH, Brier G., Weich HA, and Risau W. (1992). Vascular endothelial growth factor is a potent tumor angiogenesis factor in human gliomas in vivo. Nature (Lond) 359: 845-847.
60.
Presta LG, Chen H., O'Connor SJ, Chisholm V., Meng YG, Krummen L., Winkler M., and Ferrara N. (1997). Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders . Cancer Res.57: 4593-4599.
61.
Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, and Jardieu PM (1993). Humanization of an antibody directed against IgE . J. Immunol.151: 2623-2632.
62.
Ravindranath N., Little-Ihrig L., Phillips HS, Ferrara N., and Zeleznik AJ (1992). Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology131: 254-260.
63.
Reichman L. , Clark M., Waldmann H., and Winter G. (1988). Reshaping human antibodies for therapy. Nature (Lond) 332: 323-327.
64.
Schroff RW, Foon KA, Beatty SM, Odham RK, and Morgan AC Jr (1985). Human anti-murine immunoglobulin response in patients receiving monoclonal antibody therapy . Cancer Res.45: 879-885.
65.
Senger DR, Galli S., Dvorak AM, Perruzzi CA, Harvey VS, and Dvorak HF (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascities fluid. Science219: 983-985.
66.
Shima DT, Gougos A., Miller JW, Tolentino M., Robinson G., Adamis AP and D'Amore PA (1996). Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fasicularis. Invest. Ophthalmol. Vis. Sci.37: 1334-1340.
67.
Shiraishi S. , Nakagawa K., Kinukawa N., Nakano H., and Sueishi K. (1996). Immunohistochemical localization of vascular endothelial growth factor in human placenta. Placenta17: 111-121.
68.
Shweiki D., Itin A. Soffer D., and Keshet E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond) 359: 843-845.
69.
Sierra-Honigmann MR, Nath AK, Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, and Flores-Riveros JR (1998). Biological action of leptin as an angiogenic factor. Science281: 1683-1686.
70.
Sullivan R. and Klagsbrun M. (1985). Purification of cartilage derived growth factor by heparin affinity chromatography. J. Biol. Chem.260: 2399-2403.
71.
Terman BI, Dougher-Vermazen M., Carrion ME, Dimitrov D., Armellino DC, Gospodarowicz D., and Bohlen P. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun.187: 1579-1586.
72.
Torry DS, Holt VJ, Keenan JA, Harris G., Caudle MR, and Torry RJ (1996). Vascular endothelial growth factor expression in cycling human endometrium. Fertil. Steril.66: 72-80.
73.
Trueta J. and Amato VP (1960). The vascular contribution to osteogenesis. III. Changes in growth cartilage caused by experimentally induced ischemia. J. Bone Joint Surg.42B: 571-587.
74.
Vaisman N., Gospodarowicz D., and Neufeld G. (1990). Characterization of the receptors for vascular endothelial growth factor. J. Biol. Chem.265: 19461-19466.
75.
Warren RS, Yuan H., Matli MR, Gillett NA, and Ferrara N. (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest.95: 1789-1797.
